Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Icotinib in Advanced NSCLC Patients With Hepatic Insufficiency
NCT02062515Phase 2Unknown
- Sponsor
- Betta Pharmaceuticals
- Start
- Feb 2014
- Primary completion
- Feb 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of icotinib in non-small cell lung cancer (NSCLC), sponsored by Betta Pharmaceuticals. Primary endpoint: Number of Participants with Adverse Events at 4 weeks. Status: unknown.
02
Drugs
icotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02062515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02062515.